Phase II Study: Stereotactic Ablative Radiotherapy for Renal Tumors

STATUS

Recruiting
End date

Nov 21, 2023
participants needed

30
sponsor

University Health Network, Toronto

Send

Updated on 21 October 2022

See if I qualify

cancer

carcinoma

metastasis

kidney cancer

renal neoplasm

Summary

Renal Cell Carcinoma (RCC) is the most common type of kidney cancer. The usual treatment for this type of cancer is surgery. Considering the most common patients are an average age of 65 and some are not suitable candiates for surgery, there is great interest in non-surgical alternatives for kidney cancer treatments. This study will investigate the use of Stereotactic Ablative Radiosurgery (SABR) for renal tumors. SABR is a non-invasive alternative, which involves delivery of high doses of radiation to the target, while minimizing the risk of injury to the surrounding organs. Patients will be seen before and end of treatmetn and will be followed at 4 month intervals for up to 2 years. During the follow ups, patients will be asked to complete a quality of life questionnaire and will have standard of care imaging.

Details

Condition	Renal Tumor
Treatment	Stereotactic Ablative Radiotherapy
Clinical Study Identifier	NCT03747133
Sponsor	University Health Network, Toronto
Last Modified on	21 October 2022

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Solid Kidney Mass (primary RCC or metastasis) amenable to SABR ≤6cm
	Histological or radiological diagnosis of renal tumor
	Inoperable: High risk for surgery or declined surgery
	ECOG performance status of 0-3
Exclusion Criteria
	≥5 active metastases
	Sysstemic therapy (except endocrine therapy) wthin 6 days prior to SABR
	Prior abdominal radiotherapy with fields overlap resulting in excessive doses to the involved kidney
	Patients with end stage renal failure > 4(KDOQI guidelines)
	Familial Syndrome: Von Hippel-Lindau disease, Polycystic Kidney Disease, Hereditary Papillary RCC or Tuber Sclerosis

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Phase II Study: Stereotactic Ablative Radiotherapy for Renal Tumors